Track recorded fund announcements, transactions, leadership appointments and strategic developments from DataBane's published research.
Kedaara-backed Universal NutriScience entered a competitive sale process. Warburg Pincus was reported as frontrunner with ChrysCapital also shortlisted. The reported transaction value is INR 2,700–2,800cr. Kedaara is expected to exit if the transaction closes.
Novartis India Limited announced that ChrysCapital had completed the acquisition of a 70.68% controlling stake. The transaction marks ChrysCapital’s first majority-controlled investment in the Indian pharmaceutical sector. NIL appointed Dr. Vikas Gupta as Managing Director and CEO and announced changes to its independent directors. The company said it would adopt a new name and corporate identity following its separation from Novartis AG. The release does not disclose transaction consideration.
